A Phase I Clinical Study of MK0683 in Patients With Solid Tumors.


Phase 1
20 Years
75 Years
Not Enrolling
Both
Tumors

Thank you

Trial Information

A Phase I Clinical Study of MK0683 in Patients With Solid Tumors.


Inclusion Criteria:



- Patients with histologically or cytologically diagnosed solid tumor; no standard
therapy available or patient has failed to respond to standard therapy

Exclusion Criteria:

- Patients with history of immunotherapy, radiotherapy, surgery, or chemotherapy during
the previous 4 weeks; previous treatment is 5 or more chemotherapeutic regimens.

- Any uncontrolled concomitant illness

- Are pregnant or breast-feeding

- Serious drug or food allergy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety

Outcome Time Frame:

Duration of Trial

Safety Issue:

No

Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:

Merck

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

2005_040

NCT ID:

NCT00127127

Start Date:

June 2005

Completion Date:

August 2009

Related Keywords:

  • Tumors
  • Solid tumors

Name

Location